Howard S. Hochester, MD, discusses findings from the pooled safety analysis of TAS-102 in previously treated patients with colorectal cancer and gastric/gastroesophageal junction adenocarcinoma.
Howard S. Hochester, MD
Advertisement
Articles by Howard S. Hochester, MD
Advertisement
Latest Updated Articles
Efficacy of TAS-102 Continues to Hold Up in Metastatic CRC and Gastric CancersPublished: July 24th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
